Optimal treatment of superficial bladder tumours
Herewith you will find a complete list with all scientific publications related to EMDA.
(To download the full text, just select and double click with your left mouse key)
24. Racioppi M. et al, ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure”non muscle invasive bladder cancer: 3 years follow-up outcomes, BMC Cancer, 2018 18: 1224, https:/doi.org/10.1186/s12885-018-5134-7
23. Standpunt van de Nederlandse Vereniging voor Urologie ten aanzien van Chemohyperthermie en Electromotive Drug Administration (EMDA) bij NMIBC, Juni 2018
22. Piercontia F, Stracciaa P, et al. Cytological and histological changes in the urothelium produced by electromotive drug
administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy), Pathology - Research and Practice 213 (2017) 1078-1081
21. Josep Gual Frau, Joan Palou, Oscar Rodríguez, Ruben Parada, Alberto Breda and Humberto Villavicencio, Failure Of Bacillus Calmette-Guérin Therapy In Non-Mucleinvasive Bladder Cancer: Definition and Treatment Options, Arch. Esp. Urol. 2016; 69 (7): 423-433
20. Gan Chr, Amery S, Chatterton K, Khan MS, Thomas K, O’Brien T. Sequential BCG/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes. The Journal of Urology, Vol. 195, 1697-1703, June 2016
19. Rehme C et al. Non-muscle invasive bladder cancer: Safety of postoperative EMDA-assisted instillation of mitomycin. Urologe A. 2014 Oct 16. Epub ahead of print, doi: 10.1007/s00120-014-3649-3
18. Gan C, Amery S, Chatterton K, Khan MS, Thomas K, O’Brien TS. Sequential BCG/Electromotive drug administration (EMDA) Mitomycin C (MMC) a the standard intravesical regime in non-muscle invasive bladder cancer (NMIBC) - one year outcomes. 2014 BJU International 113, Supplement 5, 21-67
17. Gan C, Amery S, Chatterton K, Khan MS, Thomas K, O’Brien TS. Pre-operative electromotive drug Aadministration of mitomycin-C (EMDA-MMC) in newly diagnosed non muscle invasive bladder cancer (NMIBC): a pilot feasibility study. 2014 BJU International 113, Supplement 5, 21-67
16 Bachir BG, Dragomir A et al, Contemporary Cost-Effectiveness Analysis Comparing Sequential Bacillus Calmette-Guerin and Electromotive Mitomycin Versus Bacillus Calmette-Guerin Alone for Patients With High-Risk Non-Muscle-Invasive Bladder Cancer. Division of Urology, Department of Surgery, McGill University Health Center, Montreal, Quebec, Canada; Division of Urology, Department of Surgery, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada. March 2014
15. Witjes JA, O’Brien T. Fluorescent Cystoscopy VS EMDA, The Journal of Urology, Opposing Views, Vol.190, 19-21, july 2013
14 Westgeest HM, van Moorselaar RJA, Uyl-deGroot CA, Economic analysis of electromotive drug administration (EMDA) in non-muscle invasive bladder cancer, Institute of Medical Technology Assessment, Erasmus University, Rotterdam, Department of Urology VU University Medical Center. June 2013
13. Vasquez JL et al. Electroporation enhances mitomycin C cytotoxicity on T24 bladder cancer cell line: A potential improvement of intravesical chemotherapy in bladder cancer. Bioelectrochemistry 88 (2012) 127-133
12. Di Stasi et al. Intravesical sequential bacillus Calmette-Guérin and electromotive mitomycin versus bacillus Calmette-Guérin alone for stage pT1 urothelial bladder cancer, 16 years follow-up. Podium Presentation (1670) AUA 2012
11. Oosterlinck W. Electromotive mitomycin in superficial bladder cancer. Nature Reviews; Clinical Oncology. Advanced online publication 13 September 2011
10. Di Stasi SM et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. The Lancet Oncol 2011; 12: 871-79
9. Di Stasi SM, Riedl C: Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer. World J Urol, published on line on 21 February 2009
8. Sockett LJ, Borwell J et al. Electromotive drug administration (EMDA) of intravesical mitomycin-C in patients with high-risk non-invasive bladder cancer and failure of BCG immunotherapy. Abstract BAUS, BJU Int 2008; 101 (Suppl 5): 50
7. Di Stasi SM et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. The Lancet Oncol 2006, 7: 43-51
6. Di Stasi SM et al. Percutaneous sequential bacillus Calmette-Guèrin and mitomycin C for panurothelial carcinomatosis. Can J Urol 2005, 12(6): 2895-2898
5. Di Stasi SM et al. Intravesical electromotive mitomycin C versus passive transport mitomicin c for high risk superficial bladder cancer: a prospective randomized study J Urol 2003, 170: 777-782.
4. Di Stasi SM, et al. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res 1999; 59: 4912-4918.
3. Riedl CR, et al. Intravesical electromotive drug administration technique: preliminary results and side effects. J Urol 1998; 159: 1851-1856
2. Brausi M, et al. Intravesical electromotive administration (EMDA) of drugs for treatment of superficial bladder cancer: a comparative phase II study. Urol 1998; 51 (3): 506-509.
1. Di Stasi S, et al. Electromotive delivery of Mitomycin C into human bladder wall. Cancer Res 1997; 57: 875-880.